Women's willingness to accept perceived risks for vasomotor symptom relief

Journal of Women's Health

Volumn 16, Issue 7, 2007, Pages 1028-1040

  Johnson, F Reed ^a,c   Özdemir, Semra ^a   Hauber, Brett ^a   Kauf, Teresa L ^b  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HEART INFARCTION; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION; PERCEPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RATING SCALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCORING SYSTEM; SYMPTOM; VERTEBRA FRACTURE; WOMEN'S HEALTH;

ADULT; CORONARY DISEASE; DECISION MAKING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PRIMARY PREVENTION; QUALITY OF LIFE; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 34748923120     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.0218     Document Type: Article

References (28)

1. Ness J, Aronow WS, Newkirk E, McDanel D. Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. J Gerontol A Biol Sci Med Sci 2005;60:460.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321.
3. Kim N, Gross C, Curtis J, et al. The impact of clinical trials on the use of hormone replacement therapy. J Gen Intern Med 2005;20:1026.
4. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA 2004;292:1983.
5. National Institutes of Health, National Heart Lung and Blood Institute. NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. Available at www.nhlbi.nih.gov/new/press/02- 07-09.htm Accessed August 23, 2005.
6. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225.
7. Kolata G. Reversing trend, big drop is seen in breast cancer. The New York Times, 2006. Available at: www.nytimes.com/2006/12/15/health/15breast. html Accessed December 15, 2006.
8. Kolata G. Breast cancer news brings a range of reactions. The New York Times. Available at www.nytimes.com/2006/12/18/health/18breast.html Accessed December 18, 2006.
9. Louviere J, Swait J, Hensher D. Stated choice methods: Analysis and application. Cambridge, UK: Cambridge University Press, 2000.
10. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 2003;290:1729.
11. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47.
12. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673.
13. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523.
14. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016.
15. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985.
16. Kuhfeld WF, Garratt M, Tobias RD. Efficient experimental design with marketing research applications. J Marketing Res 1994;31:545.
17. Dey A. Orthogonal fractional factorial designs. New York: Halstead Press, 1985.
18. Huber J, Zwerina KB. The importance of utility balance in efficient choice designs. J Marketing Res 1996;33:307.
19. Harris Interactive. Who we are. Available at www.harrisinteractive. com/about/ Accessed February 10, 2004.
20. Greene WB. Econometric analysis, 4th ed. New York: Prentice-Hall, 2000.
21. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual Life Outcomes 2005;3:47.
22. Levens E, Williams RS. Current opinions and understandings of menopausal women about hormone replacement therapy (HRT): The University of Florida experience. Am J Obstet Gynecol 2004;191:641.
23. McIntosh J, Blalock SJ. Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm 2005;62:69.
24. Buchanan T, Smith JL. Using the Internet for psychological research: Personality testing on the World Wide Web. Br J Psychol 1999;90:125.
25. Brennan RM, Crespo CJ, Wactawski-Wende J. Health behaviors and other characteristics of women on hormone therapy: Results from the Third National Health and Nutrition Examination Survey, 1988-1994. Menopause 2004;11:536.
26. U.S. Bureau of the Census. Current population survey. Washington, DC : The Bureau, 2004.
27. Paulos JA. Innumeracy: Mathematical illiteracy and its consequences. New York: Hill and Wang, 1988.
28. Edwards A, Elwyn G, Mulley A. Explaining risks: Turning numerical data into meaningful pictures. BMJ 2002;324:827.